CADL - Erasca, Candle, Xencor drop as BofA downgrades on lack of near-term catalysts September, 03 2025 03:14 PM Candel Therapeutics Inc. 2025-09-03 15:14:48 ET More on Erasca, Xencor, etc. Candel Therapeutics announces $15M in direct offering Incyte granted FDA label expansion for lymphoma therapy Monjuvi Seeking Alpha’s Quant Rating on Erasca Historical earnings data for Erasca Financial information for Erasca For further details see: Erasca, Candle, Xencor drop as BofA downgrades on lack of near-term catalysts